We provide you with 20 years of free, institutional-grade data for RCUS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RCUS. Explore the full financial landscape of RCUS stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-06 | 1724521 | RCUS | 10-Q | Url |
| 2025-05-06 | 1724521 | RCUS | 10-Q | Url |
| 2025-02-25 | 1724521 | RCUS | 10-K | Url |
| 2024-11-06 | 1724521 | RCUS | 10-Q | Url |
| 2024-08-08 | 1724521 | RCUS | 10-Q | Url |
| 2024-05-08 | 1724521 | RCUS | 10-Q | Url |
| 2024-02-21 | 1724521 | RCUS | 10-K | Url |
| 2023-11-07 | 1724521 | RCUS | 10-Q | Url |
| 2023-08-07 | 1724521 | RCUS | 10-Q | Url |
| 2023-05-09 | 1724521 | RCUS | 10-Q | Url |
| 2023-02-28 | 1724521 | RCUS | 10-K | Url |
| 2022-11-02 | 1724521 | RCUS | 10-Q | Url |
| 2022-08-03 | 1724521 | RCUS | 10-Q | Url |
| 2022-05-09 | 1724521 | RCUS | 10-Q | Url |
| 2022-02-23 | 1724521 | RCUS | 10-K | Url |
| 2021-11-08 | 1724521 | RCUS | 10-Q | Url |
| 2021-08-05 | 1724521 | RCUS | 10-Q | Url |
| 2021-05-05 | 1724521 | RCUS | 10-Q | Url |
| 2021-02-25 | 1724521 | RCUS | 10-K | Url |
| 2020-11-05 | 1724521 | RCUS | 10-Q | Url |
| 2020-08-06 | 1724521 | RCUS | 10-Q | Url |
| 2020-05-05 | 1724521 | RCUS | 10-Q | Url |
| 2020-03-05 | 1724521 | RCUS | 10-K | Url |
| 2019-11-05 | 1724521 | RCUS | 10-Q | Url |
| 2019-08-06 | 1724521 | RCUS | 10-Q | Url |
| 2019-05-02 | 1724521 | RCUS | 10-Q | Url |
| 2019-03-05 | 1724521 | RCUS | 10-K | Url |
| 2018-11-08 | 1724521 | RCUS | 10-Q | Url |
| 2018-08-06 | 1724521 | RCUS | 10-Q | Url |
| 2018-05-09 | 1724521 | RCUS | 10-Q | Url |
| 2018-02-16 | 1724521 | RCUS | S-1 | Url |
Arcus Biosciences, Inc(NYSE:RCUS) 
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 a...
Website: http://www.arcusbio.com
Founded: 2015
Full Time Employees: 139
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about RCUS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.